1|ENGROSSED SENATE |
|BILL NO. 1257 By: Hamilton of the Senate |
2| |
| and |
3| |
| Turner of the House |
4| |
| |
5| |
| |
6| An Act relating to the Uniform Controlled Dangerous |
| Substances Act; amending 63 O.S. 2021, Section 2-101, |
7| as last amended by Section 8, Chapter 343, O.S.L. |
| 2025 (63 O.S. Supp. 2025, Section 2-101), which |
8| relates to definitions; modifying terms; amending 63 |
| O.S. 2021, Section 2-204, as last amended by Section |
9| 3, Chapter 308, O.S.L. 2024 (63 O.S. Supp. 2025, |
| Section 2-204), which relates to Schedule I; adding |
10| substance; amending 63 O.S. 2021, Section 2-208, |
| which relates to Schedule III; adding substance; |
11| removing substance; conforming statutory language; |
| and providing an effective date. |
12| |
| |
13| |
| |
14|BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: |
| |
15| SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-101, as |
| |
16|last amended by Section 8, Chapter 343, O.S.L. 2025 (63 O.S. Supp. |
| |
17|2025, Section 2-101), is amended to read as follows: |
| |
18| Section 2-101. As used in the Uniform Controlled Dangerous |
| |
19|Substances Act: |
| |
20| 1. "Acute pain" means pain, whether resulting from disease, |
| |
21|accidental trauma, intentional trauma, or other cause that the |
| |
22|practitioner reasonably expects to last only a short period of time. |
| |
23| Acute pain does not include chronic pain, pain being treated as |
| |
24| |
| |
Page 1
___________________________________________________________________________
1|part of cancer care, hospice or other end-of-life care, or pain |
| |
2|being treated as part of palliative care; |
| |
3| 2. "Administer" means the direct application of a controlled |
| |
4|dangerous substance, whether by injection, inhalation, ingestion or |
| |
5|any other means, to the body of a patient, animal or research |
| |
6|subject by: |
| |
7| a. a practitioner (or, in the presence of the |
| |
8| practitioner, by the authorized agent of the |
| |
9| practitioner), or |
| |
10| b. the patient or research subject at the direction and |
| |
11| in the presence of the practitioner; |
| |
12| 3. "Agent" means a peace officer appointed by and who acts on |
| |
13|behalf of the Director of the Oklahoma State Bureau of Narcotics and |
| |
14|Dangerous Drugs Control or an authorized person who acts on behalf |
| |
15|of or at the direction of a person who manufactures, distributes, |
| |
16|dispenses, prescribes, administers or uses for scientific purposes |
| |
17|controlled dangerous substances but does not include a common or |
| |
18|contract carrier, public warehouser or employee thereof, or a person |
| |
19|required to register under the Uniform Controlled Dangerous |
| |
20|Substances Act; |
| |
21| 4. "Anhydrous ammonia" means any substance that exhibits |
| |
22|cryogenic evaporative behavior and tests positive for ammonia; |
| |
23| 5. "Board" means the Advisory Board to the Director of the |
| |
24|Oklahoma State Bureau of Narcotics and Dangerous Drugs Control; |
| |
Page 2
___________________________________________________________________________
1| 6. "Bureau" means the Oklahoma State Bureau of Narcotics and |
| |
2|Dangerous Drugs Control; |
| |
3| 7. "Chronic pain" means pain that persists beyond the usual |
| |
4|course of an acute disease or healing of an injury. Chronic pain |
| |
5|may or may not be associated with an acute or chronic pathologic |
| |
6|process that causes continuous or intermittent pain over months or |
| |
7|years; |
| |
8| 8. "Coca leaves" includes cocaine and any compound, |
| |
9|manufacture, salt, derivative, mixture or preparation of coca |
| |
10|leaves, except derivatives of coca leaves which do not contain |
| |
11|cocaine or ecgonine; |
| |
12| 9. "Commissioner" or "Director" means the Director of the |
| |
13|Oklahoma State Bureau of Narcotics and Dangerous Drugs Control; |
| |
14| 10. "Control" means to add, remove or change the placement of a |
| |
15|drug, substance or immediate precursor under the Uniform Controlled |
| |
16|Dangerous Substances Act; |
| |
17| 11. "Controlled dangerous substance" means a drug, substance or |
| |
18|immediate precursor in Schedules I through V of the Uniform |
| |
19|Controlled Dangerous Substances Act or any drug, substance or |
| |
20|immediate precursor listed either temporarily or permanently as a |
| |
21|federally controlled substance. Any conflict between state and |
| |
22|federal law with regard to the particular schedule in which a |
| |
23|substance is listed shall be resolved in favor of state law; |
| |
24| |
| |
Page 3
___________________________________________________________________________
1| 12. "Counterfeit substance" means a controlled substance which, |
| |
2|or the container or labeling of which without authorization, bears |
| |
3|the trademark, trade name or other identifying marks, imprint, |
| |
4|number or device or any likeness thereof of a manufacturer, |
| |
5|distributor or dispenser other than the person who in fact |
| |
6|manufactured, distributed or dispensed the substance; |
| |
7| 13. "Deliver" or "delivery" means the actual, constructive or |
| |
8|attempted transfer from one person to another of a controlled |
| |
9|dangerous substance or drug paraphernalia, whether or not there is |
| |
10|an agency relationship; |
| |
11| 14. "Dispense" means to deliver a controlled dangerous |
| |
12|substance to an ultimate user or human research subject by or |
| |
13|pursuant to the lawful order of a practitioner, including the |
| |
14|prescribing, administering, packaging, labeling or compounding |
| |
15|necessary to prepare the substance for such distribution. |
| |
16|"Dispenser" is a practitioner who delivers a controlled dangerous |
| |
17|substance to an ultimate user or human research subject; |
| |
18| 15. "Distribute" means to deliver other than by administering |
| |
19|or dispensing a controlled dangerous substance; |
| |
20| 16. "Distributor" means a commercial entity engaged in the |
| |
21|distribution or reverse distribution of narcotics and dangerous |
| |
22|drugs and who complies with all regulations promulgated by the |
| |
23|federal Drug Enforcement Administration and the Oklahoma State |
| |
24|Bureau of Narcotics and Dangerous Drugs Control; |
| |
Page 4
___________________________________________________________________________
1| 17. "Drug" means articles: |
| |
2| a. recognized in the official United States Pharmacopeia, |
| |
3| official Homeopathic Pharmacopoeia of the United |
| |
4| States, or official National Formulary, or any |
| |
5| supplement to any of them, |
| |
6| b. intended for use in the diagnosis, cure, mitigation, |
| |
7| treatment or prevention of disease in man or other |
| |
8| animals, |
| |
9| c. other than food, intended to affect the structure or |
| |
10| any function of the body of man or other animals, and |
| |
11| d. intended for use as a component of any article |
| |
12| specified in this paragraph; |
| |
13|provided, however, the term drug does not include devices or their |
| |
14|components, parts or accessories; |
| |
15| 18. "Drug paraphernalia" means all equipment, products, and |
| |
16|materials of any kind which are used, intended for use, or fashioned |
| |
17|specifically for use in planting, propagating, cultivating, growing, |
| |
18|harvesting, manufacturing, compounding, converting, producing, |
| |
19|processing, preparing, testing, analyzing, packaging, repackaging, |
| |
20|storing, containing, concealing, injecting, ingesting, inhaling, or |
| |
21|otherwise introducing into the human body, a controlled dangerous |
| |
22|substance in violation of the Uniform Controlled Dangerous |
| |
23|Substances Act including, but not limited to: |
| |
24| |
| |
Page 5
___________________________________________________________________________
1| a. kits used, intended for use, or fashioned |
| |
2| specifically for use in planting, propagating, |
| |
3| cultivating, growing, or harvesting of any species of |
| |
4| plant which is a controlled dangerous substance or |
| |
5| from which a controlled dangerous substance can be |
| |
6| derived, |
| |
7| b. kits used, intended for use, or fashioned |
| |
8| specifically for use in manufacturing, compounding, |
| |
9| converting, producing, processing, or preparing |
| |
10| controlled dangerous substances, |
| |
11| c. isomerization devices used, intended for use, or |
| |
12| fashioned specifically for use in increasing the |
| |
13| potency of any species of plant which is a controlled |
| |
14| dangerous substance, |
| |
15| d. testing equipment used, intended for use, or |
| |
16| fashioned specifically for use in identifying or in |
| |
17| analyzing the strength, effectiveness, or purity of |
| |
18| controlled dangerous substances, |
| |
19| e. scales and balances used, intended for use, or |
| |
20| fashioned specifically for use in weighing or |
| |
21| measuring controlled dangerous substances, |
| |
22| f. diluents and adulterants, such as quinine |
| |
23| hydrochloride, mannitol, mannite, dextrose, and |
| |
24| |
| |
Page 6
___________________________________________________________________________
1| lactose used, intended for use, or fashioned |
| |
2| specifically for use in cutting controlled dangerous |
| |
3| substances, |
| |
4| g. separation gins and sifters used, intended for use, |
| |
5| or fashioned specifically for use in removing twigs |
| |
6| and seeds from, or in otherwise cleaning or refining, |
| |
7| marijuana, |
| |
8| h. blenders, bowls, containers, spoons, and mixing |
| |
9| devices used, intended for use, or fashioned |
| |
10| specifically for use in compounding controlled |
| |
11| dangerous substances, |
| |
12| i. capsules, balloons, envelopes, and other containers |
| |
13| used, intended for use, or fashioned specifically for |
| |
14| use in packaging small quantities of controlled |
| |
15| dangerous substances, |
| |
16| j. containers and other objects used, intended for use, |
| |
17| or fashioned specifically for use in parenterally |
| |
18| injecting controlled dangerous substances into the |
| |
19| human body, |
| |
20| k. hypodermic syringes, needles, and other objects used, |
| |
21| intended for use, or fashioned specifically for use in |
| |
22| parenterally injecting controlled dangerous substances |
| |
23| into the human body, except as authorized by Section |
| |
24| 2-1101 of this title, |
| |
Page 7
___________________________________________________________________________
1| l. objects used, intended for use, or fashioned |
| |
2| specifically for use in ingesting, inhaling, or |
| |
3| otherwise introducing marijuana, cocaine, hashish, or |
| |
4| hashish oil into the human body, such as: |
| |
5| (1) metal, wooden, acrylic, glass, stone, plastic, |
| |
6| or ceramic pipes with or without screens, |
| |
7| permanent screens, hashish heads, or punctured |
| |
8| metal bowls, |
| |
9| (2) water pipes, |
| |
10| (3) carburetion tubes and devices, |
| |
11| (4) smoking and carburetion masks, |
| |
12| (5) roach clips, meaning objects used to hold |
| |
13| burning material, such as a marijuana cigarette, |
| |
14| that has become too small or too short to be held |
| |
15| in the hand, |
| |
16| (6) miniature cocaine spoons and cocaine vials, |
| |
17| (7) chamber pipes, |
| |
18| (8) carburetor pipes, |
| |
19| (9) electric pipes, |
| |
20| (10) air-driven pipes, |
| |
21| (11) chillums, |
| |
22| (12) bongs, or |
| |
23| (13) ice pipes or chillers, |
| |
24| m. all hidden or novelty pipes, and |
| |
Page 8
___________________________________________________________________________
1| n. any pipe that has a tobacco bowl or chamber of less |
| |
2| than one-half (1/2) inch in diameter in which there is |
| |
3| any detectable residue of any controlled dangerous |
| |
4| substance as defined in this section or any other |
| |
5| substances not legal for possession or use; |
| |
6|provided, however, the term drug paraphernalia shall not include |
| |
7|separation gins intended for use in preparing tea or spice, clamps |
| |
8|used for constructing electrical equipment, water pipes designed for |
| |
9|ornamentation in which no detectable amount of an illegal substance |
| |
10|is found or pipes designed and used solely for smoking tobacco, |
| |
11|traditional pipes of an American Indian tribal religious ceremony, |
| |
12|antique pipes that are thirty (30) years of age or older, or drug |
| |
13|testing strips possessed by a person for purposes of determining the |
| |
14|presence of fentanyl or a fentanyl-related compound; |
| |
15| 19. "Drug-dependent person" means a person who is using a |
| |
16|controlled dangerous substance and who is in a state of psychic or |
| |
17|physical dependence, or both, arising from administration of that |
| |
18|controlled dangerous substance on a continuous basis. Drug |
| |
19|dependence is characterized by behavioral and other responses which |
| |
20|include a strong compulsion to take the substance on a continuous |
| |
21|basis in order to experience its psychic effects, or to avoid the |
| |
22|discomfort of its absence; |
| |
23| 20. "Harm-reduction services" means programs established to: |
| |
24| |
| |
Page 9
___________________________________________________________________________
1| a. reduce the spread of infectious diseases related to |
| |
2| injection drug use, |
| |
3| b. reduce drug dependency, overdose deaths, and |
| |
4| associated complications, and |
| |
5| c. increase safe recovery and disposal of used syringes |
| |
6| and sharp waste; |
| |
7| 21. "Hazardous materials" means materials, whether solid, |
| |
8|liquid, or gas, which are toxic to human, animal, aquatic, or plant |
| |
9|life, and the disposal of such materials is controlled by state or |
| |
10|federal guidelines; |
| |
11| 22. "Home care agency" means any sole proprietorship, |
| |
12|partnership, association, corporation, or other organization which |
| |
13|administers, offers, or provides home care services, for a fee or |
| |
14|pursuant to a contract for such services, to clients in their place |
| |
15|of residence; |
| |
16| 23. "Home care services" means skilled or personal care |
| |
17|services provided to clients in their place of residence for a fee; |
| |
18| 24. "Hospice" means a centrally administered, nonprofit or |
| |
19|for-profit, medically directed, nurse-coordinated program which |
| |
20|provides a continuum of home and inpatient care for the terminally |
| |
21|ill patient and the patient's family. Such term shall also include |
| |
22|a centrally administered, nonprofit or for-profit, medically |
| |
23|directed, nurse-coordinated program if such program is licensed |
| |
24|pursuant to the provisions of the Uniform Controlled Dangerous |
| |
Page 10
___________________________________________________________________________
1|Substances Act. A hospice program offers palliative and supportive |
| |
2|care to meet the special needs arising out of the physical, |
| |
3|emotional and spiritual stresses which are experienced during the |
| |
4|final stages of illness and during dying and bereavement. This care |
| |
5|is available twenty-four (24) hours a day, seven (7) days a week, |
| |
6|and is provided on the basis of need, regardless of ability to pay. |
| |
7|"Class A" Hospice refers to Medicare-certified hospices. "Class B" |
| |
8|refers to all other providers of hospice services; |
| |
9| 25. "Imitation controlled substance" means a substance that is |
| |
10|not a controlled dangerous substance, which by dosage unit |
| |
11|appearance, color, shape, size, markings or by representations made, |
| |
12|would lead a reasonable person to believe that the substance is a |
| |
13|controlled dangerous substance, or is a drug intended solely for |
| |
14|veterinary purposes that is not a controlled dangerous substance and |
| |
15|is being used outside of the scope of practice or normal course of |
| |
16|business, as defined by the State Board of Veterinary Medical |
| |
17|Examiners, or is a federal Food and Drug Administration-approved |
| |
18|drug that is not a controlled dangerous substance and is being used |
| |
19|outside the scope of approval for illicit purposes such as |
| |
20|adulterating or lacing other controlled dangerous substances. In |
| |
21|the event the appearance of the dosage unit or use is not reasonably |
| |
22|sufficient to establish that the substance is an imitation |
| |
23|controlled substance, the court or authority concerned should |
| |
24|consider, in addition to all other factors, the following factors: |
| |
Page 11
___________________________________________________________________________
1| a. statements made by an owner or by any other person in |
| |
2| control of the substance concerning the nature of the |
| |
3| substance, or its use or effect, |
| |
4| b. statements made to the recipient that the substance |
| |
5| may be resold for inordinate profit, |
| |
6| c. whether the substance is packaged in a manner normally |
| |
7| used for illicit controlled substances, |
| |
8| d. evasive tactics or actions utilized by the owner or |
| |
9| person in control of the substance to avoid detection |
| |
10| by law enforcement authorities, |
| |
11| e. prior convictions, if any, of an owner, or any other |
| |
12| person in control of the object, under state or |
| |
13| federal law related to controlled substances or fraud, |
| |
14| and |
| |
15| f. the proximity of the substances to controlled |
| |
16| dangerous substances; |
| |
17| 26. "Immediate precursor" means a substance which the Director |
| |
18|has found to be and by regulation designates as being the principal |
| |
19|compound commonly used or produced primarily for use, and which is |
| |
20|an immediate chemical intermediary used, or likely to be used, in |
| |
21|the manufacture of a controlled dangerous substance, the control of |
| |
22|which is necessary to prevent, curtail or limit such manufacture; |
| |
23| 27. "Initial prescription" means a prescription issued to a |
| |
24|patient who: |
| |
Page 12
___________________________________________________________________________
1| a. has never previously been issued a prescription for |
| |
2| the drug or its pharmaceutical equivalent in the past |
| |
3| year, or |
| |
4| b. requires a prescription for the drug or its |
| |
5| pharmaceutical equivalent due to a surgical procedure |
| |
6| or new acute event and has previously had a |
| |
7| prescription for the drug or its pharmaceutical |
| |
8| equivalent within the past year. |
| |
9| When determining whether a patient was previously issued a |
| |
10|prescription for a drug or its pharmaceutical equivalent, the |
| |
11|practitioner shall consult with the patient and review the medical |
| |
12|record and prescription monitoring information of the patient; |
| |
13| 28. "Isomer" means the optical isomer, except as used in |
| |
14|subsections C and F of Section 2-204 of this title and paragraph 4 |
| |
15|of subsection A of Section 2-206 of this title. As used in |
| |
16|subsections C and F of Section 2-204 of this title, isomer means the |
| |
17|optical, positional, or geometric isomer. As used in paragraph 4 of |
| |
18|subsection A of Section 2-206 of this title, the term isomer means |
| |
19|the optical or geometric isomer; |
| |
20| 29. "Laboratory" means a laboratory approved by the Director as |
| |
21|proper to be entrusted with the custody of controlled dangerous |
| |
22|substances and the use of controlled dangerous substances for |
| |
23|scientific and medical purposes and for purposes of instruction; |
| |
24| |
| |
Page 13
___________________________________________________________________________
1| 30. "Manufacture" means the production, preparation, | | | 2|propagation, compounding or processing of a controlled dangerous | | | 3|substance, either directly or indirectly by extraction from | | | 4|substances of natural or synthetic origin, or independently by means | | | 5|of chemical synthesis or by a combination of extraction and chemical | | | 6|synthesis. "Manufacturer" includes any person who packages, | | | 7|repackages or labels any container of any controlled dangerous | | | 8|substance, except practitioners who dispense or compound | | | 9|prescription orders for delivery to the ultimate consumer; | | | 10| 31. "Marijuana" means all parts of the Cannabis plantCannabis| | | 11|sativa L., whether growing or not; the seeds thereof; the resin | | | 12|extracted from any part of such plant; and every compound, | | | 13|manufacture, salt, derivative, mixture, or preparation of such | | | 14|plant, its seeds, or resin; tetrahydrocannabinols, neutral | | | 15|compounds, and their corresponding acids, including synthetic | | | 16|equivalents of the substances contained in the Cannabis plant or in | | | 17|the resinous extractives of Cannabis, or synthetic substances, | | | 18|derivatives, and their isomers with similar chemical structure and | | | 19|pharmacological activity, but shall not include: | | | 20| a. the mature stalks of such plant or fiber produced | | | 21| from such stalks, | | | 22| b. oil or cake made from the seeds of such plant, | | | 23| including cannabidiol derived from the seeds of the | | | 24| marijuana plant, | | | Page 14 ___________________________________________________________________________
1| c. any other compound, manufacture, salt, derivative, |
| |
2| mixture or preparation of such mature stalks (except |
| |
3| the resin extracted therefrom), including cannabidiol |
| |
4| derived from mature stalks, fiber, oil or cake, |
| |
5| d. the sterilized seed of such plant which is incapable |
| |
6| of germination, |
| |
7| e. for any person participating in a clinical trial to |
| |
8| administer cannabidiol for the treatment of severe |
| |
9| forms of epilepsy pursuant to Section 2-802 of this |
| |
10| title, a drug or substance approved by the federal |
| |
11| Food and Drug Administration for use by those |
| |
12| participants, |
| |
13| f. for any person or the parents, legal guardians or |
| |
14| caretakers of the person who have received a written |
| |
15| certification from a physician licensed in this state |
| |
16| that the person has been diagnosed by a physician as |
| |
17| having Lennox-Gastaut syndrome, Dravet syndrome, also |
| |
18| known as severe myoclonic epilepsy of infancy, or any |
| |
19| other severe form of epilepsy that is not adequately |
| |
20| treated by traditional medical therapies, spasticity |
| |
21| due to multiple sclerosis or due to paraplegia, |
| |
22| intractable nausea and vomiting, appetite stimulation |
| |
23| with chronic wasting diseases, the substance |
| |
24| cannabidiol, a nonpsychoactive cannabinoid, found in |
| |
Page 15
___________________________________________________________________________
1| the Cannabis plantCannabis sativa L.or any other | | | 2| preparation thereof, that has a tetrahydrocannabinol | | | 3| concentration not more than three-tenths of one | | | 4| percent (0.3%) and that is delivered to the patient in | | | 5| the form of a liquid, | | | 6| g. any federal Food and Drug Administration-approved | | | 7| drug or substance, or | | | 8| h. industrial hemp, from the Cannabis plantCannabis| | | 9|sativa L.and any part of such plant, whether growing | | | 10| or not, with a combined delta-9 tetrahydrocannabinol | | | 11| and tetrahydrocannabinolic acid concentration not more | | | 12| than three-tenths of one percent (0.3%) on a | | | 13| dry-weight basis, as tested using post-decarboxylation | | | 14| or other similarly reliable methods, which shall only | | | 15| be grown pursuant to the Oklahoma Industrial Hemp | | | 16| Program and may be shipped intrastate and interstate; | | | 17| 32. "Medical purpose" means an intention to utilize a | | | 18|controlled dangerous substance for physical or mental treatment, for | | | 19|diagnosis, or for the prevention of a disease condition not in | | | 20|violation of any state or federal law and not for the purpose of | | | 21|satisfying physiological or psychological dependence or other abuse; | | | 22| 33. "Mid-level practitioner" means an Advanced Practice | | | 23|Registered Nurse as defined and within parameters specified in | | | 24|Section 567.3a of Title 59 of the Oklahoma Statutes, or a certified | | | Page 16 ___________________________________________________________________________
1|animal euthanasia technician as defined in Section 698.2 of Title 59 |
| |
2|of the Oklahoma Statutes, or an animal control officer registered by |
| |
3|the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control |
| |
4|under subsection B of Section 2-301 of this title within the |
| |
5|parameters of such officer's duties under Sections 501 through 508 |
| |
6|of Title 4 of the Oklahoma Statutes; |
| |
7| 34. "Narcotic drug" means any of the following, whether |
| |
8|produced directly or indirectly by extraction from substances of |
| |
9|vegetable origin, or independently by means of chemical synthesis, |
| |
10|or by a combination of extraction and chemical synthesis: |
| |
11| a. opium, coca leaves and opiates, |
| |
12| b. a compound, manufacture, salt, derivative or |
| |
13| preparation of opium, coca leaves or opiates, |
| |
14| c. cocaine, its salts, optical and geometric isomers, and |
| |
15| salts of isomers, |
| |
16| d. ecgonine, its derivatives, their salts, isomers and |
| |
17| salts of isomers, and |
| |
18| e. a substance, and any compound, manufacture, salt, |
| |
19| derivative or preparation thereof, which is chemically |
| |
20| identical with any of the substances referred to in |
| |
21| subparagraphs a through d of this paragraph, except |
| |
22| that the words narcotic drug as used in Section 2-101 |
| |
23| et seq. of this title shall not include decocainized |
| |
24| |
| |
Page 17
___________________________________________________________________________
1| coca leaves or extracts of coca leaves, which extracts |
| |
2| do not contain cocaine or ecgonine; |
| |
3| 35. "Opiate" or "opioid" means any Schedule II, III, IV or V |
| |
4|substance having an addiction-forming or addiction-sustaining |
| |
5|liability similar to morphine or being capable of conversion into a |
| |
6|drug having such addiction-forming or addiction-sustaining |
| |
7|liability. The terms do not include, unless specifically designated |
| |
8|as controlled under the Uniform Controlled Dangerous Substances Act, |
| |
9|the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its |
| |
10|salts (dextromethorphan). The terms do include the racemic and |
| |
11|levorotatory forms; |
| |
12| 36. "Opium poppy" means the plant of the species Papaver |
| |
13|somniferum L., except the seeds thereof; |
| |
14| 37. "Palliative care" means a specialized medical service for |
| |
15|people of any age and at any stage of a serious illness or |
| |
16|life-altering medical event that focuses on navigating complex |
| |
17|medical decisions while providing patient autonomy and access to |
| |
18|information. Utilizing a holistic and interdisciplinary team |
| |
19|approach, palliative care addresses physical, intellectual, |
| |
20|emotional, social, and spiritual needs. Palliative care may be |
| |
21|provided in the inpatient, outpatient, or home care setting and |
| |
22|strives to improve quality of life for both the patient and the |
| |
23|family; |
| |
24| |
| |
Page 18
___________________________________________________________________________
1| 38. "Patient-provider agreement" means a written contract or |
| |
2|agreement that is executed between a practitioner and a patient |
| |
3|prior to the commencement of treatment for chronic pain using an |
| |
4|opioid drug as a means to: |
| |
5| a. explain the possible risk of development of physical |
| |
6| or psychological dependence in the patient and prevent |
| |
7| the possible development of addiction, |
| |
8| b. document the understanding of both the practitioner |
| |
9| and the patient regarding the patient-provider |
| |
10| agreement of the patient, |
| |
11| c. establish the rights of the patient in association |
| |
12| with treatment and the obligations of the patient in |
| |
13| relation to the responsible use, discontinuation of |
| |
14| use, and storage of opioid drugs, including any |
| |
15| restrictions on the refill of prescriptions or the |
| |
16| acceptance of opioid prescriptions from practitioners, |
| |
17| d. identify the specific medications and other modes of |
| |
18| treatment, including physical therapy or exercise, |
| |
19| relaxation, or psychological counseling, that are |
| |
20| included as a part of the patient-provider agreement, |
| |
21| e. specify the measures the practitioner may employ to |
| |
22| monitor the compliance of the patient including, but |
| |
23| not limited to, random specimen screens and pill |
| |
24| counts, and |
| |
Page 19
___________________________________________________________________________
1| f. delineate the process for terminating the agreement, |
| |
2| including the consequences if the practitioner has |
| |
3| reason to believe that the patient is not complying |
| |
4| with the terms of the agreement. Compliance with the |
| |
5| consent items described in this paragraph shall |
| |
6| constitute a valid, informed consent for opioid |
| |
7| therapy. The practitioner shall be held harmless from |
| |
8| civil litigation for failure to treat pain if the |
| |
9| event occurs because of nonadherence by the patient |
| |
10| with any of the provisions of the patient-provider |
| |
11| agreement; |
| |
12| 39. "Peace officer" means a police officer, sheriff, deputy |
| |
13|sheriff, district attorney's investigator, investigator from the |
| |
14|Office of the Attorney General, or any other person elected or |
| |
15|appointed by law to enforce any of the criminal laws of this state |
| |
16|or of the United States; |
| |
17| 40. "Person" means an individual, corporation, government or |
| |
18|governmental subdivision or agency, business trust, estate, trust, |
| |
19|partnership or association, or any other legal entity; |
| |
20| 41. "Poppy straw" means all parts, except the seeds, of the |
| |
21|opium poppy, after mowing; |
| |
22| 42. "Practitioner" means: |
| |
23| a. (1) a medical doctor or osteopathic physician, |
| |
24| (2) a dentist, |
| |
Page 20
___________________________________________________________________________
1| (3) a podiatrist, |
| |
2| (4) an optometrist, |
| |
3| (5) a veterinarian, |
| |
4| (6) an Advanced Practice Registered Nurse under the |
| |
5| supervision of a licensed medical doctor or |
| |
6| osteopathic physician, or a physician assistant, |
| |
7| (7) a scientific investigator, or |
| |
8| (8) any other person, |
| |
9| licensed, registered or otherwise permitted to |
| |
10| prescribe, distribute, dispense, conduct research with |
| |
11| respect to, use for scientific purposes or administer |
| |
12| a controlled dangerous substance in the course of |
| |
13| professional practice or research in this state, or |
| |
14| b. a pharmacy, hospital, laboratory or other institution |
| |
15| licensed, registered or otherwise permitted to |
| |
16| distribute, dispense, conduct research with respect |
| |
17| to, use for scientific purposes or administer a |
| |
18| controlled dangerous substance in the course of |
| |
19| professional practice or research in this state; |
| |
20| 43. "Production" includes the manufacture, planting, |
| |
21|cultivation, growing or harvesting of a controlled dangerous |
| |
22|substance; |
| |
23| 44. "Serious illness" means a medical illness or physical |
| |
24|injury or condition that substantially affects quality of life for |
| |
Page 21
___________________________________________________________________________
1|more than a short period of time. Serious illness includes, but is |
| |
2|not limited to, Alzheimer's disease or related dementias, lung |
| |
3|disease, cancer, heart failure, renal failure, liver failure, or |
| |
4|chronic, unremitting, or intractable pain such as neuropathic pain; |
| |
5| 45. "State" means the State of Oklahoma or any other state of |
| |
6|the United States; |
| |
7| 46. "Straw person" or "straw party", also known as a "front", |
| |
8|means a third party who: |
| |
9| a. is put up in name only to take part in a transaction |
| |
10| or otherwise is a nominal party to a transaction with |
| |
11| no actual control, |
| |
12| b. acts on behalf of another person to obtain title to |
| |
13| property and executes documents and instruments the |
| |
14| principal may direct respecting property, or |
| |
15| c. purchases property for another for the purpose of |
| |
16| concealing the identity of the real purchaser or to |
| |
17| accomplish some purpose otherwise in violation of the |
| |
18| Oklahoma Statutes; |
| |
19| 47. "Surgical procedure" means a procedure that is performed |
| |
20|for the purpose of structurally altering the human body by incision |
| |
21|or destruction of tissues as part of the practice of medicine. This |
| |
22|term includes the diagnostic or therapeutic treatment of conditions |
| |
23|or disease processes by use of instruments such as lasers, |
| |
24|ultrasound, ionizing, radiation, scalpels, probes, or needles that |
| |
Page 22
___________________________________________________________________________
1|cause localized alteration or transportation of live human tissue by |
| |
2|cutting, burning, vaporizing, freezing, suturing, probing, or |
| |
3|manipulating by closed reduction for major dislocations or |
| |
4|fractures, or otherwise altering by any mechanical, thermal, |
| |
5|light-based, electromagnetic, or chemical means; |
| |
6| 48. a. "Synthetic controlled substance" means a substance: |
| |
7| (1) the chemical structure of which is substantially |
| |
8| similar to the chemical structure of a controlled |
| |
9| dangerous substance in Schedule I or II, |
| |
10| (2) which has a stimulant, depressant, or |
| |
11| hallucinogenic effect on the central nervous |
| |
12| system that is substantially similar to or |
| |
13| greater than the stimulant, depressant, or |
| |
14| hallucinogenic effect on the central nervous |
| |
15| system of a controlled dangerous substance in |
| |
16| Schedule I or II, or |
| |
17| (3) with respect to a particular person, which such |
| |
18| person represents or intends to have a stimulant, |
| |
19| depressant, or hallucinogenic effect on the |
| |
20| central nervous system that is substantially |
| |
21| similar to or greater than the stimulant, |
| |
22| depressant, or hallucinogenic effect on the |
| |
23| central nervous system of a controlled dangerous |
| |
24| substance in Schedule I or II. |
| |
Page 23
___________________________________________________________________________
1| b. The designation of gamma-butyrolactone or any other |
| |
2| chemical as a precursor, pursuant to Section 2-322 of |
| |
3| this title, does not preclude a finding pursuant to |
| |
4| subparagraph a of this paragraph that the chemical is |
| |
5| a synthetic controlled substance. |
| |
6| c. Synthetic controlled substance does not include: |
| |
7| (1) a controlled dangerous substance, |
| |
8| (2) any substance for which there is an approved new |
| |
9| drug application, |
| |
10| (3) with respect to a particular person any |
| |
11| substance, if an exemption is in effect for |
| |
12| investigational use, for that person under the |
| |
13| provisions of Section 505 of the Federal Food, |
| |
14| Drug, and Cosmetic Act, 21 U.S.C., Section 355, |
| |
15| to the extent conduct with respect to such |
| |
16| substance is pursuant to such exemption, or |
| |
17| (4) any substance to the extent not intended for |
| |
18| human consumption before such an exemption takes |
| |
19| effect with respect to that substance. |
| |
20| d. Prima facie evidence that a substance containing |
| |
21| salvia divinorum has been enhanced, concentrated, or |
| |
22| chemically or physically altered shall give rise to a |
| |
23| rebuttable presumption that the substance is a |
| |
24| synthetic controlled substance; |
| |
Page 24
___________________________________________________________________________
1| 49. "Tetrahydrocannabinols"meansincludes all substances that | | | 2|have been chemically synthesized to emulate the | | | 3|tetrahydrocannabinols of marijuana, specifically including any | | | 4|tetrahydrocannabinols derived from industrial hemp; and | | | 5| 50. "Ultimate user" means a person who lawfully possesses a | | | 6|controlled dangerous substance for the person's own use or for the | | | 7|use of a member of the person's household or for administration to | | | 8|an animal owned by the person or by a member of the person's | | | 9|household. | | | 10| SECTION 2. AMENDATORY 63 O.S. 2021, Section 2-204, as | | | 11|last amended by Section 3, Chapter 308, O.S.L. 2024 (63 O.S. Supp. | | | 12|2025, Section 2-204), is amended to read as follows: | | | 13| Section 2-204. The controlled substances listed in this section | | | 14|are included in Schedule I and include any material, compound, | | | 15|mixture, or preparation that contains any quantity of the following | | | 16|hallucinogenic substances, their salts, isomers, and salts of | | | 17|isomers, unless specifically excepted, when the existence of these | | | 18|salts, isomers, and salts of isomers is possible within the specific | | | 19|chemical designation. | | | 20| A. Any of the following opiates including their isomers, | | | 21|esters, ethers, salts, and salts of isomers, esters, and ethers, | | | 22|unless specifically excepted, when the existence of these isomers, | | | 23|esters, ethers, and salts is possible within the specific chemical | | | 24|designation: | | | Page 25 ___________________________________________________________________________
1| 1. Acetylmethadol; |
| |
2| 2. Allylprodine; |
| |
3| 3. Alphacetylmethadol; |
| |
4| 4. Alphameprodine; |
| |
5| 5. Alphamethadol; |
| |
6| 6. Benzethidine; |
| |
7| 7. Betacetylmethadol; |
| |
8| 8. Betameprodine; |
| |
9| 9. Betamethadol; |
| |
10| 10. Betaprodine; |
| |
11| 11. Clonitazene; |
| |
12| 12. Dextromoramide; |
| |
13| 13. Dextrorphan (except its methyl ether); |
| |
14| 14. Diampromide; |
| |
15| 15. Diethylthiambutene; |
| |
16| 16. Dimenoxadol; |
| |
17| 17. Dimepheptanol; |
| |
18| 18. Dimethylthiambutene; |
| |
19| 19. Dioxaphetyl butyrate; |
| |
20| 20. Dipipanone; |
| |
21| 21. Ethylmethylthiambutene; |
| |
22| 22. Etonitazene; |
| |
23| 23. Etoxeridine; |
| |
24| 24. Furethidine; |
| |
Page 26
___________________________________________________________________________
1| 25. Hydroxypethidine; |
| |
2| 26. Isotonitazene; |
| |
3| 27. Ketobemidone; |
| |
4| 28. Levomoramide; |
| |
5| 29. Levophenacylmorphan; |
| |
6| 30. Metonitazene; |
| |
7| 31. Morpheridine; |
| |
8| 32. N-desethyl isotonitazene; |
| |
9| 33. N-pyrrolidino protonitazene; |
| |
10| 34. Noracymethadol; |
| |
11| 35. Norlevorphanol; |
| |
12| 36. Normethadone; |
| |
13| 37. Norpipanone; |
| |
14| 38. Phenadoxone; |
| |
15| 39. Phenampromide; |
| |
16| 40. Phenomorphan; |
| |
17| 41. Phenoperidine; |
| |
18| 42. Piritramide; |
| |
19| 43. Proheptazine; |
| |
20| 44. Properidine; |
| |
21| 45. Protonitazene; |
| |
22| 46. Racemoramide; or |
| |
23| 47. Trimeperidine. |
| |
24| |
| |
Page 27
___________________________________________________________________________
1| B. Any of the following opium derivatives, their salts, |
| |
2|isomers, and salts of isomers, unless specifically excepted, when |
| |
3|the existence of these salts, isomers, and salts of isomers is |
| |
4|possible within the specific chemical designation: |
| |
5| 1. Acetorphine; |
| |
6| 2. Acetyldihydrocodeine; |
| |
7| 3. Benzylmorphine; |
| |
8| 4. Codeine methylbromide; |
| |
9| 5. Codeine-N-Oxide; |
| |
10| 6. Cyprenorphine; |
| |
11| 7. Desomorphine; |
| |
12| 8. Dihydromorphine; |
| |
13| 9. Etorphine; |
| |
14| 10. Heroin; |
| |
15| 11. Hydromorphinol; |
| |
16| 12. Methyldesorphine; |
| |
17| 13. Methylhydromorphine; |
| |
18| 14. Morphine methylbromide; |
| |
19| 15. Morphine methylsulfonate; |
| |
20| 16. Morphine-N-Oxide; |
| |
21| 17. Myrophine; |
| |
22| 18. Nicocodeine; |
| |
23| 19. Nicomorphine; |
| |
24| 20. Normorphine; |
| |
Page 28
___________________________________________________________________________
1| 21. Phoclodine; |
| |
2| 22. Thebacon; |
| |
3| 23. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide |
| |
4|(Acetyl fentanyl); |
| |
5| 24. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butenamide |
| |
6|(Crotonyl fentanyl); |
| |
7| 25. |
| |
8|N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-furancarboxamide |
| |
9|(Furanyl fentanyl); |
| |
10| 26. N-phenyl-1-(2-phenylethyl)-4-piperidinamine (4-ANPP); |
| |
11| 27. |
| |
12|N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide |
| |
13|(Cyclopropyl fentanyl); or |
| |
14| 28. N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide |
| |
15|(Butyrl fentanyl). |
| |
16| C. Any material, compound, mixture, or preparation which |
| |
17|contains any quantity of the following hallucinogenic substances, |
| |
18|their salts, isomers, and salts of isomers, unless specifically |
| |
19|excepted, when the existence of these salts, isomers, and salts of |
| |
20|isomers is possible within the specific chemical designation: |
| |
21| 1. Methcathinone; |
| |
22| 2. 3, 4-methylenedioxy amphetamine; |
| |
23| 3. 3, 4-methylenedioxy methamphetamine; |
| |
24| 4. 5-methoxy-3, 4-methylenedioxy amphetamine; |
| |
Page 29
___________________________________________________________________________
1| 5. 3, 4, 5-trimethoxy amphetamine; |
| |
2| 6. Bufotenine; |
| |
3| 7. Diethyltryptamine; |
| |
4| 8. Dimethyltryptamine; |
| |
5| 9. 4-methyl-2, 5-dimethoxyamphetamine; |
| |
6| 10. Ibogaine; |
| |
7| 11. Lysergic acid diethylamide; |
| |
8| 12. Marijuana; |
| |
9| 13. Mescaline; |
| |
10| 14. N-benzylpiperazine; |
| |
11| 15. N-ethyl-3-piperidyl benzilate; |
| |
12| 16. N-methyl-3-piperidyl benzilate; |
| |
13| 17. Psilocybin; |
| |
14| 18. Psilocyn; |
| |
15| 19. 2, 5 dimethoxyamphetamine; |
| |
16| 20. 4 Bromo-2, 5-dimethoxyamphetamine; |
| |
17| 21. 4 methoxyamphetamine; |
| |
18| 22. Cyclohexamine; |
| |
19| 23. Salvia Divinorum; |
| |
20| 24. Salvinorin A; |
| |
21| 25. Thiophene Analog of Phencyclidine. Also known as: |
| |
22|1-(1-(2-thienyl) cyclohexyl) piperidine; 2-Thienyl Analog of |
| |
23|Phencyclidine; TPCP, TCP; |
| |
24| 26. Phencyclidine (PCP); |
| |
Page 30
___________________________________________________________________________
1| 27. Pyrrolidine Analog for Phencyclidine. Also known as |
| |
2|1-(1-Phenylcyclohexyl) - Pyrrolidine, PCPy, PHP; |
| |
3| 28. 1-(3-trifluoromethylphenyl) piperazine; |
| |
4| 29. Flunitrazepam; |
| |
5| 30. B-hydroxy-amphetamine; |
| |
6| 31. B-ketoamphetamine; |
| |
7| 32. 2,5-dimethoxy-4-nitroamphetamine; |
| |
8| 33. 2,5-dimethoxy-4-bromophenethylamine; |
| |
9| 34. 2,5-dimethoxy-4-chlorophenethylamine; |
| |
10| 35. 2,5-dimethoxy-4-iodoamphetamine; |
| |
11| 36. 2,5-dimethoxy-4-iodophenethylamine; |
| |
12| 37. 2,5-dimethoxy-4-methylphenethylamine; |
| |
13| 38. 2,5-dimethoxy-4-ethylphenethylamine; |
| |
14| 39. 2,5-dimethoxy-4-fluorophenethylamine; |
| |
15| 40. 2,5-dimethoxy-4-nitrophenethylamine; |
| |
16| 41. 2,5-dimethoxy-4-ethylthio-phenethylamine; |
| |
17| 42. 2,5-dimethoxy-4-isopropylthio-phenethylamine; |
| |
18| 43. 2,5-dimethoxy-4-propylthio-phenethylamine; |
| |
19| 44. 2,5-dimethoxy-4-cyclopropylmethylthio-phenethylamine; |
| |
20| 45. 2,5-dimethoxy-4-tert-butylthio-phenethylamine; |
| |
21| 46. 2,5-dimethoxy-4-(2-fluoroethylthio)-phenethylamine; |
| |
22| 47. 5-methoxy-N, N-dimethyltryptamine; |
| |
23| 48. N-methyltryptamine; |
| |
24| 49. A-ethyltryptamine; |
| |
Page 31
___________________________________________________________________________
1| 50. A-methyltryptamine; |
| |
2| 51. N, N-diethyltryptamine; |
| |
3| 52. N, N-diisopropyltryptamine; |
| |
4| 53. N, N-dipropyltryptamine; |
| |
5| 54. 5-methoxy-a-methyltryptamine; |
| |
6| 55. 4-hydroxy-N, N-diethyltryptamine; |
| |
7| 56. 4-hydroxy-N, N-diisopropyltryptamine; |
| |
8| 57. 5-methoxy-N, N-diisopropyltryptamine; |
| |
9| 58. 4-hydroxy-N-isopropyl-N-methyltryptamine; |
| |
10| 59. 3,4-Methylenedioxymethcathinone (Methylone); |
| |
11| 60. 3,4-Methylenedioxypyrovalerone (MDPV); |
| |
12| 61. 3-Methylmethcathinone (Metaphedrone); |
| |
13| 62. 4-Methylmethcathinone (Mephedrone); |
| |
14| 63. 4-methoxymethcathinone; |
| |
15| 64. 4-Fluoromethcathinone; |
| |
16| 65. 3-Fluoromethcathinone; |
| |
17| 66. 1-(8-bromobenzo 1,2-b;4,5-b' difuran-4-yl)-2-aminopropane; |
| |
18| 67. 2,5-Dimethoxy-4-chloroamphetamine; |
| |
19| 68. 4-Methylethcathinone; |
| |
20| 69. Pyrovalerone; |
| |
21| 70. N,N-diallyl-5-methoxytryptamine; |
| |
22| 71. 3,4-Methylenedioxy-N-ethylcathinone (Ethylone); |
| |
23| 72. B-keto-N-Methylbenzodioxolylbutanamine (Butylone); |
| |
24| 73. B-keto-Methylbenzodioxolylpentanamine (Pentylone); |
| |
Page 32
___________________________________________________________________________
1| 74. Alpha-Pyrrolidinopentiophenone; |
| |
2| 75. 4-Fluoroamphetamine; |
| |
3| 76. Pentedrone; |
| |
4| 77. 4'-Methyl-a-pyrrolidinohexaphenone; |
| |
5| 78. 2,5-dimethoxy-4-(n)-propylphenethylamine; |
| |
6| 79. 2,5-dimethoxyphenethylamine; |
| |
7| 80. 1,4-Dibenzylpiperazine; |
| |
8| 81. N,N-Dimethylamphetamine; |
| |
9| 82. 4-Fluoromethamphetamine; |
| |
10| 83. 4-Chloro-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine |
| |
11|(25C-NBOMe); |
| |
12| 84. 4-Iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine |
| |
13|(25I-NBOMe); |
| |
14| 85. 4-Bromo-2,5-dimethoxy-N-(2-methoxybenzy)phenethylamine |
| |
15|(25B-NBOMe); |
| |
16| 86. 1-(4-Fluorophenyl)piperazine; |
| |
17| 87. Methoxetamine; |
| |
18| 88. |
| |
19|3,4-dichloro-N[2-dimethylamino)cyclohexyl]-N-methylbenzamide; |
| |
20| 89. N-ethyl hexadrone; |
| |
21| 90. Isopropyl-U-47700; |
| |
22| 91. Para-fluorobutyrl fentanyl; |
| |
23| 92. Para-fluorofentanyl (pFF); |
| |
24| 93. Fluoro isobutryrl fentanyl; |
| |
Page 33
___________________________________________________________________________
1| 94. 3-Hydroxy Phencyclidine (PCP); | | | 2| 95. 3-methoxy Phencyclidine (PCP); | | | 3| 96. Flualprazolam;or| | | 4| 97. Flubromazolam; or | | | 5| 98. Tetrahydrocannabinol. | | | 6| D. Unless specifically excepted or unless listed in a different | | | 7|schedule, any material, compound, mixture, or preparation which | | | 8|contains any quantity of the following substances having stimulant | | | 9|or depressant effect on the central nervous system: | | | 10| 1. Fenethylline; | | | 11| 2. Mecloqualone; | | | 12| 3. N-ethylamphetamine; | | | 13| 4. Methaqualone; | | | 14| 5. Gamma-Hydroxybutyric Acid, also known as GHB, | | | 15|gamma-hydroxybutyrate, 4-hydroxybutyrate, 4-hydroxybutanoic acid, | | | 16|sodium oxybate, and sodium oxybutyrate; | | | 17| 6. Gamma-Butyrolactone (GBL) as packaged, marketed, | | | 18|manufactured, or promoted for human consumption, with the exception | | | 19|of legitimate food additive and manufacturing purposes; | | | 20| 7. Gamma Hydroxyvalerate (GHV) as packaged, marketed, or | | | 21|manufactured for human consumption, with the exception of legitimate | | | 22|food additive and manufacturing purposes; | | | 23| | | | 24| | | | Page 34 ___________________________________________________________________________
1| 8. Gamma Valerolactone (GVL) as packaged, marketed, or |
| |
2|manufactured for human consumption, with the exception of legitimate |
| |
3|food additive and manufacturing purposes; |
| |
4| 9. 1,4 Butanediol (1,4 BD or BDO) as packaged, marketed, |
| |
5|manufactured, or promoted for human consumption with the exception |
| |
6|of legitimate manufacturing purposes; or |
| |
7| 10. N-ethylpentylone. |
| |
8| E. 1. The following industrial uses of Gamma-Butyrolactone, |
| |
9|Gamma Hydroxyvalerate, Gamma Valerolactone, or 1,4 Butanediol are |
| |
10|excluded from all schedules of controlled substances under this |
| |
11|title: |
| |
12| a. pesticides, |
| |
13| b. photochemical etching, |
| |
14| c. electrolytes of small batteries or capacitors, |
| |
15| d. viscosity modifiers in polyurethane, |
| |
16| e. surface etching of metal coated plastics, |
| |
17| f. organic paint disbursements for water soluble inks, |
| |
18| g. pH regulators in the dyeing of wool and polyamide |
| |
19| fibers, |
| |
20| h. foundry chemistry as a catalyst during curing, |
| |
21| i. curing agents in many coating systems based on |
| |
22| urethanes and amides, |
| |
23| j. additives and flavoring agents in food, |
| |
24| confectionary, and beverage products, |
| |
Page 35
___________________________________________________________________________
1| k. synthetic fiber and clothing production, |
| |
2| l. tetrahydrofuran production, |
| |
3| m. gamma butyrolactone production, |
| |
4| n. polybutylene terephthalate resin production, |
| |
5| o. polyester raw materials for polyurethane elastomers |
| |
6| and foams, |
| |
7| p. coating resin raw material, and |
| |
8| q. as an intermediate in the manufacture of other |
| |
9| chemicals and pharmaceuticals. |
| |
10| 2. At the request of any person, the Director of the Oklahoma |
| |
11|State Bureau of Narcotics and Dangerous Drugs Control may exempt any |
| |
12|other product containing Gamma-Butyrolactone, Gamma Hydroxyvalerate, |
| |
13|Gamma Valerolactone, or 1,4 Butanediol from being included as a |
| |
14|Schedule I controlled substance if such product is labeled, |
| |
15|marketed, manufactured, and distributed for legitimate industrial |
| |
16|use in a manner that reduces or eliminates the likelihood of abuse. |
| |
17| 3. In making a determination regarding an industrial product, |
| |
18|the Director, after notice and hearing, shall consider the |
| |
19|following: |
| |
20| a. the history and current pattern of abuse, |
| |
21| b. the name and labeling of the product, |
| |
22| c. the intended manner of distribution, advertising, and |
| |
23| promotion of the product, and |
| |
24| |
| |
Page 36
___________________________________________________________________________
1| d. other factors as may be relevant to and consistent |
| |
2| with the public health and safety. |
| |
3| 4. The hearing shall be held in accordance with the procedures |
| |
4|of the Administrative Procedures Act. |
| |
5| F. Any material, compound, mixture, or preparation, whether |
| |
6|produced directly or indirectly from a substance of vegetable origin |
| |
7|or independently by means of chemical synthesis, or by a combination |
| |
8|of extraction and chemical synthesis, that contains any quantity of |
| |
9|the following substances, or that contains any of their salts, |
| |
10|isomers, and salts of isomers when the existence of these salts, |
| |
11|isomers, and salts of isomers is possible within the specific |
| |
12|chemical designation: |
| |
13| 1. JWH-004; |
| |
14| 2. JWH-007; |
| |
15| 3. JWH-009; |
| |
16| 4. JWH-015; |
| |
17| 5. JWH-016; |
| |
18| 6. JWH-018; |
| |
19| 7. JWH-019; |
| |
20| 8. JWH-020; |
| |
21| 9. JWH-030; |
| |
22| 10. JWH-046; |
| |
23| 11. JWH-047; |
| |
24| 12. JWH-048; |
| |
Page 37
___________________________________________________________________________
1| 13. JWH-049; |
| |
2| 14. JWH-050; |
| |
3| 15. JWH-070; |
| |
4| 16. JWH-071; |
| |
5| 17. JWH-072; |
| |
6| 18. JWH-073; |
| |
7| 19. JWH-076; |
| |
8| 20. JWH-079; |
| |
9| 21. JWH-080; |
| |
10| 22. JWH-081; |
| |
11| 23. JWH-082; |
| |
12| 24. JWH-094; |
| |
13| 25. JWH-096; |
| |
14| 26. JWH-098; |
| |
15| 27. JWH-116; |
| |
16| 28. JWH-120; |
| |
17| 29. JWH-122; |
| |
18| 30. JWH-145; |
| |
19| 31. JWH-146; |
| |
20| 32. JWH-147; |
| |
21| 33. JWH-148; |
| |
22| 34. JWH-149; |
| |
23| 35. JWH-150; |
| |
24| 36. JWH-156; |
| |
Page 38
___________________________________________________________________________
1| 37. JWH-167; |
| |
2| 38. JWH-175; |
| |
3| 39. JWH-180; |
| |
4| 40. JWH-181; |
| |
5| 41. JWH-182; |
| |
6| 42. JWH-184; |
| |
7| 43. JWH-185; |
| |
8| 44. JWH-189; |
| |
9| 45. JWH-192; |
| |
10| 46. JWH-193; |
| |
11| 47. JWH-194; |
| |
12| 48. JWH-195; |
| |
13| 49. JWH-196; |
| |
14| 50. JWH-197; |
| |
15| 51. JWH-198; |
| |
16| 52. JWH-199; |
| |
17| 53. JWH-200; |
| |
18| 54. JWH-201; |
| |
19| 55. JWH-202; |
| |
20| 56. JWH-203; |
| |
21| 57. JWH-204; |
| |
22| 58. JWH-205; |
| |
23| 59. JWH-206; |
| |
24| 60. JWH-207; |
| |
Page 39
___________________________________________________________________________
1| 61. JWH-208; |
| |
2| 62. JWH-209; |
| |
3| 63. JWH-210; |
| |
4| 64. JWH-211; |
| |
5| 65. JWH-212; |
| |
6| 66. JWH-213; |
| |
7| 67. JWH-234; |
| |
8| 68. JWH-235; |
| |
9| 69. JWH-236; |
| |
10| 70. JWH-237; |
| |
11| 71. JWH-239; |
| |
12| 72. JWH-240; |
| |
13| 73. JWH-241; |
| |
14| 74. JWH-242; |
| |
15| 75. JWH-243; |
| |
16| 76. JWH-244; |
| |
17| 77. JWH-245; |
| |
18| 78. JWH-246; |
| |
19| 79. JWH-248; |
| |
20| 80. JWH-249; |
| |
21| 81. JWH-250; |
| |
22| 82. JWH-251; |
| |
23| 83. JWH-252; |
| |
24| 84. JWH-253; |
| |
Page 40
___________________________________________________________________________
1| 85. JWH-262; |
| |
2| 86. JWH-292; |
| |
3| 87. JWH-293; |
| |
4| 88. JWH-302; |
| |
5| 89. JWH-303; |
| |
6| 90. JWH-304; |
| |
7| 91. JWH-305; |
| |
8| 92. JWH-306; |
| |
9| 93. JWH-307; |
| |
10| 94. JWH-308; |
| |
11| 95. JWH-311; |
| |
12| 96. JWH-312; |
| |
13| 97. JWH-313; |
| |
14| 98. JWH-314; |
| |
15| 99. JWH-315; |
| |
16| 100. JWH-316; |
| |
17| 101. JWH-346; |
| |
18| 102. JWH-348; |
| |
19| 103. JWH-363; |
| |
20| 104. JWH-364; |
| |
21| 105. JWH-365; |
| |
22| 106. JWH-367; |
| |
23| 107. JWH-368; |
| |
24| 108. JWH-369; |
| |
Page 41
___________________________________________________________________________
1| 109. JWH-370; |
| |
2| 110. JWH-371; |
| |
3| 111. JWH-373; |
| |
4| 112. JWH-386; |
| |
5| 113. JWH-387; |
| |
6| 114. JWH-392; |
| |
7| 115. JWH-394; |
| |
8| 116. JWH-395; |
| |
9| 117. JWH-397; |
| |
10| 118. JWH-398; |
| |
11| 119. JWH-399; |
| |
12| 120. JWH-400; |
| |
13| 121. JWH-412; |
| |
14| 122. JWH-413; |
| |
15| 123. JWH-414; |
| |
16| 124. JWH-415; |
| |
17| 125. CP-55, 940; |
| |
18| 126. CP-47, 497; |
| |
19| 127. HU-210; |
| |
20| 128. HU-211; |
| |
21| 129. WIN-55, 212-2; |
| |
22| 130. AM-2201; |
| |
23| 131. AM-2233; |
| |
24| 132. JWH-018 adamantyl-carboxamide; |
| |
Page 42
___________________________________________________________________________
1| 133. AKB48; |
| |
2| 134. JWH-122 N-(4-pentenyl)analog; |
| |
3| 135. MAM2201; |
| |
4| 136. URB597; |
| |
5| 137. URB602; |
| |
6| 138. URB754; |
| |
7| 139. UR144; |
| |
8| 140. XLR11; |
| |
9| 141. A-796,260; |
| |
10| 142. STS-135; |
| |
11| 143. AB-FUBINACA; |
| |
12| 144. AB-PINACA; |
| |
13| 145. PB-22; |
| |
14| 146. AKB48 N-5-Fluorpentyl; |
| |
15| 147. AM1248; |
| |
16| 148. FUB-PB-22; |
| |
17| 149. ADB-FUBINACA; |
| |
18| 150. BB-22; |
| |
19| 151. 5-Fluoro PB-22; or |
| |
20| 152. 5-Fluoro AKB-48. |
| |
21| G. In addition to those substances listed in subsection F of |
| |
22|this section, unless specifically excepted or unless listed in |
| |
23|another schedule, any material, compound, mixture, or preparation |
| |
24| |
| |
Page 43
___________________________________________________________________________
1|which contains any quantity of a synthetic cannabinoid found to be |
| |
2|in any of the following chemical groups: |
| |
3| 1. Naphthoylindoles: any compound containing a |
| |
4|3-(1-naphthoyl)indole structure with or without substitution at the |
| |
5|nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, |
| |
6|alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, |
| |
7|1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, |
| |
8|1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- |
| |
9|morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, |
| |
10|phenyl, or halophenyl group, whether or not further substituted on |
| |
11|the indole ring to any extent, and whether or not substituted on the |
| |
12|naphthyl ring to any extent. Naphthoylindoles include, but are not |
| |
13|limited to: |
| |
14| a. 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole |
| |
15| (JWH-200), |
| |
16| b. 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (AM2201), |
| |
17| c. 1-pentyl-3-(1-naphthoyl)indole (JWH-018), |
| |
18| d. 1-butyl-3-(1-naphthoyl)indole (JWH-073), |
| |
19| e. 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081), |
| |
20| f. 1-propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015), |
| |
21| g. 1-hexyl-3-(1-naphthoyl)indole (JWH-019), |
| |
22| h. 1-pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122), |
| |
23| i. 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210), |
| |
24| j. 1-pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398), |
| |
Page 44
___________________________________________________________________________
1| k. 1-pentyl-2-methyl-3-(1-naphthoyl)indole (JWH-007), |
| |
2| l. 1-pentyl-3-(7-methoxy-1-naphthoyl)indole (JWH-164), |
| |
3| m. 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole |
| |
4| (JWH-098), |
| |
5| n. 1-pentyl-3-(4-fluoro-1-naphthoyl)indole (JWH-412), |
| |
6| o. |
| |
7| 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(1-naphthoyl)in |
| |
8| dole (AM-1220), |
| |
9| p. 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole |
| |
10| (MAM-2201), or |
| |
11| q. 1-(4-cyanobutyl)-3-(1-naphthoyl)indole (AM-2232); |
| |
12| 2. Naphthylmethylindoles: any compound containing a |
| |
13|1H-indol-3-yl-(1-naphthyl)methane structure with or without |
| |
14|substitution at the nitrogen atom of the indole ring by an alkyl, |
| |
15|haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
| |
16|benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, |
| |
17|2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, |
| |
18|1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, |
| |
19|1-methylazepanyl, phenyl, or halophenyl group, whether or not |
| |
20|further substituted on the indole ring to any extent, and whether or |
| |
21|not substituted on the naphthyl ring to any extent. |
| |
22|Naphthylmethylindoles include, but are not limited to, |
| |
23|(1-pentylindol-3-yl)(1-naphthyl)methane (JWH-175); |
| |
24| |
| |
Page 45
___________________________________________________________________________
1| 3. Naphthoylpyrroles: any compound containing a |
| |
2|3-(1-naphthoyl)pyrrole structure with or without substitution at the |
| |
3|nitrogen atom of the pyrrole ring by an alkyl, haloalkyl, |
| |
4|cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, |
| |
5|halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, |
| |
6|2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, |
| |
7|1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, |
| |
8|1-methylazepanyl, phenyl, or halophenyl group, whether or not |
| |
9|further substituted on the pyrrole ring to any extent, and whether |
| |
10|or not substituted on the naphthyl group to any extent. |
| |
11|Naphthoylpyrroles include, but are not limited to: |
| |
12| a. 1-hexyl-2-phenyl-4-(1-naphthoyl)pyrrole (JWH-147), |
| |
13| b. 1-pentyl-5-(2-methylphenyl)-3-(1-naphthoyl)pyrrole |
| |
14| (JWH-370), |
| |
15| c. 1-pentyl-3-(1-naphthoyl)pyrrole (JWH-030), or |
| |
16| d. 1-hexyl-5-phenyl-3-(1-naphthoyl)pyrrole (JWH-147); |
| |
17| 4. Naphthylideneindenes: any compound containing a |
| |
18|1-(1-naphthylmethylene)indene structure with or without substitution |
| |
19|at the 3-position of the indene ring by an alkyl, haloalkyl, |
| |
20|cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, |
| |
21|halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, |
| |
22|2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, |
| |
23|1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, |
| |
24|1-methylazepanyl, phenyl, or halophenyl group, whether or not |
| |
Page 46
___________________________________________________________________________
1|further substituted on the indene group to any extent, and whether |
| |
2|or not substituted on the naphthyl group to any extent. |
| |
3|Naphthylmethylindenes include, but are not limited to, |
| |
4|(1-[(3-pentyl)-1H-inden-1-ylidene)methyl]naphthalene (JWH-176); |
| |
5| 5. Phenylacetylindoles: any compound containing a |
| |
6|3-phenylacetylindole structure with or without substitution at the |
| |
7|nitrogen atom of the indole ring by alkyl, haloalkyl, cyanoalkyl, |
| |
8|alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, |
| |
9|1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, |
| |
10|1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- |
| |
11|morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, |
| |
12|phenyl, or halophenyl group, whether or not further substituted on |
| |
13|the indole ring to any extent, and whether or not substituted on the |
| |
14|phenyl ring to any extent. Phenylacetylindoles include, but are not |
| |
15|limited to: |
| |
16| a. 1-pentyl-3-(2-methoxyphenylacetyl)indole (JWH-250), |
| |
17| b. 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole |
| |
18| (RCS-8), |
| |
19| c. 1-pentyl-3-(2-chlorophenylacetyl)indole (JWH-203), |
| |
20| d. 1-pentyl-3-(2-methylphenylacetyl)indole (JWH-251), |
| |
21| e. 1-pentyl-3-(4-methoxyphenylacetyl)indole (JWH-201), |
| |
22| or |
| |
23| f. 1-pentyl-3-(3-methoxyphenylacetyl)indole (JWH-302); |
| |
24| |
| |
Page 47
___________________________________________________________________________
1| 6. Cyclohexylphenols: any compound containing a |
| |
2|2-(3-hydroxycyclohexyl)phenol structure with or without substitution |
| |
3|at the 5-position of the phenolic ring by an alkyl, haloalkyl, |
| |
4|cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, |
| |
5|halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, |
| |
6|2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, |
| |
7|1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, |
| |
8|1-methylazepanyl, phenyl, or halophenyl group, and whether or not |
| |
9|further substituted on the cyclohexyl ring to any extent. |
| |
10|Cyclohexylphenols include, but are not limited to: |
| |
11| a. |
| |
12| 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl] |
| |
13| -phenol (CP-47,497), |
| |
14| b. |
| |
15| 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]- |
| |
16| phenol (cannabicyclohexanol; CP-47,497 C8 homologue), |
| |
17| or |
| |
18| c. |
| |
19| 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydro |
| |
20| xypropyl)cyclohexyl]-phenol (CP 55, 940); |
| |
21| 7. Benzoylindoles: any compound containing a 3-(benzoyl)indole |
| |
22|structure with or without substitution at the nitrogen atom of the |
| |
23|indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, |
| |
24|cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, |
| |
Page 48
___________________________________________________________________________
1|1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, |
| |
2|1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- |
| |
3|morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, |
| |
4|phenyl, or halophenyl group, whether or not further substituted on |
| |
5|the indole ring to any extent, and whether or not substituted on the |
| |
6|phenyl group to any extent. Benzoylindoles include, but are not |
| |
7|limited to: |
| |
8| a. 1-pentyl-3-(4-methoxybenzoyl)indole (RCS-4), |
| |
9| b. |
| |
10| 1-[2-(4-morpholinyl)ethyl]-2-methyl-3-(4-methoxybenzoy |
| |
11| l)indole (Pravadoline or WIN 48, 098), |
| |
12| c. 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694), |
| |
13| d. 1-pentyl-3-(2-iodobenzoyl)indole (AM-679), or |
| |
14| e. |
| |
15| 1-[1-(N-methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl) |
| |
16| indole (AM-2233); |
| |
17| 8. Cyclopropoylindoles: Any compound containing a |
| |
18|3-(cyclopropoyl)indole structure with substitution at the nitrogen |
| |
19|atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, |
| |
20|cycloalkylmethyl, cycloalkylethyl, benzyl, halobenzyl, |
| |
21|1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, |
| |
22|1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3- |
| |
23|morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, 1-methylazepanyl, |
| |
24|phenyl, or halophenyl group, whether or not further substituted in |
| |
Page 49
___________________________________________________________________________
1|the indole ring to any extent, and whether or not substituted in the |
| |
2|cyclopropoyl ring to any extent. Cyclopropoylindoles include, but |
| |
3|are not limited to: |
| |
4| a. 1-pentyl-3-(2,2,3,3-tetramethylcyclopropoyl)indole |
| |
5| (UR-144), |
| |
6| b. |
| |
7| 1-(5-chloropentyl)-3-(2,2,3,3-tetramethylcyclopropoyl) |
| |
8| indole (5Cl-UR-144), or |
| |
9| c. |
| |
10| 1-(5-fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropoyl) |
| |
11| indole (XLR11); |
| |
12| 9. Indole Amides: Any compound containing a |
| |
13|1H-Indole-3-carboxamide structure with or without substitution at |
| |
14|the nitrogen atom of the indole ring by an alkyl, haloalkyl, |
| |
15|cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, |
| |
16|halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, |
| |
17|2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, |
| |
18|1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, |
| |
19|1-methylazepanyl, phenyl, or halophenyl group, whether or not |
| |
20|substituted at the carboxamide group by an adamantyl, naphthyl, |
| |
21|phenyl, benzyl, quinolinyl, cycloalkyl, |
| |
22|1-amino-3-methyl-1-oxobutan-2-yl, |
| |
23|1-amino-3,3-dimethyl-1-oxobutan-2-yl, |
| |
24|1-methoxy-3-methyl-1-oxobutan-2-yl, |
| |
Page 50
___________________________________________________________________________
1|1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether |
| |
2|or not further substituted in the indole, adamantyl, naphthyl, |
| |
3|phenyl, pyrrole, quninolinyl, or cycloalkyl rings to any extent. |
| |
4|Indole Amides include, but are not limited to: |
| |
5| a. N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide |
| |
6| (2NE1), |
| |
7| b. |
| |
8| N-(1-adamantyl)-1-(5-fluoropentyl-1H-indole-3-carboxam |
| |
9| ide (STS-135), |
| |
10| c. |
| |
11| N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-i |
| |
12| ndole-3-carboxamide (ADBICA), |
| |
13| d. |
| |
14| N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluorope |
| |
15| ntyl)-1H-indole-3-carboxamide (5F-ADBICA), |
| |
16| e. N-(naphthalen-1-yl)-1-pentyl-1H-indole-3-carboxamide |
| |
17| (NNE1), |
| |
18| f. |
| |
19| 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-ca |
| |
20| rboxamide (5F-NNE1), |
| |
21| g. N-benzyl-1-pentyl-1H-indole-3-carboxamide (SDB-006), |
| |
22| or |
| |
23| h. N-benzyl-1-(5-fluoropentyl)-1H-indole-3-carboxamide |
| |
24| (5F-SDB-006); |
| |
Page 51
___________________________________________________________________________
1| 10. Indole Esters: Any compound containing a |
| |
2|1H-Indole-3-carboxylate structure with or without substitution at |
| |
3|the nitrogen atom of the indole ring by an alkyl, haloalkyl, |
| |
4|cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, |
| |
5|halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, |
| |
6|2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, |
| |
7|1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, |
| |
8|1-methylazepanyl, phenyl, or halophenyl group, whether or not |
| |
9|substituted at the carboxylate group by an adamantyl, naphthyl, |
| |
10|phenyl, benzyl, quinolinyl, cycloalkyl, |
| |
11|1-amino-3-methyl-1-oxobutan-2-yl, |
| |
12|1-amino-3,3-dimethyl-1-oxobutan-2-yl, |
| |
13|1-methoxy-3-methyl-1-oxobutan-2-yl, |
| |
14|1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether |
| |
15|or not further substituted in the indole, adamantyl, naphthyl, |
| |
16|phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. |
| |
17|Indole Esters include, but are not limited to: |
| |
18| a. quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate |
| |
19| (PB-22), |
| |
20| b. quinolin-8-yl |
| |
21| 1-(5-fluoropentyl)-1H-indole-3-carboxylate (5F-PB-22), |
| |
22| c. quinolin-8-yl |
| |
23| 1-(cyclohexylmethyl)-1H-indole-3-carboxylate (BB-22), |
| |
24| |
| |
Page 52
___________________________________________________________________________
1| d. naphthalen-1-yl |
| |
2| 1-(4-fluorobenzyl)-1H-indole-3-carboxylate |
| |
3| (FDU-PB-22), or |
| |
4| e. naphthalen-1-yl |
| |
5| 1-(5-fluoropentyl)-1H-indole-3-carboxylate (NM2201); |
| |
6| 11. Adamantanoylindoles: Any compound containing an |
| |
7|adamantanyl-(1H-indol-3-yl)methanone structure with or without |
| |
8|substitution at the nitrogen atom of the indole ring by an alkyl, |
| |
9|haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, |
| |
10|benzyl, halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, |
| |
11|2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, |
| |
12|1-(N-methyl-3- morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, |
| |
13|1-methylazepanyl, phenyl, or halophenyl group, whether or not |
| |
14|further substituted in the indole ring to any extent, and whether or |
| |
15|not substituted in the adamantyl ring to any extent. |
| |
16|Adamantanoylindoles include, but are not limited to: |
| |
17| a. |
| |
18| adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-i |
| |
19| ndol-3-yl]methanone (AM1248), or |
| |
20| b. adamantan-1-yl-(1-pentyl-1H-indol-3-yl)methanone |
| |
21| (AB-001); |
| |
22| 12. Carbazole Ketone: Any compound containing |
| |
23|(9H-carbazole-3-yl) methanone structure with or without substitution |
| |
24|at the nitrogen atom of the carbazole ring by an alkyl, haloalkyl, |
| |
Page 53
___________________________________________________________________________
1|cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, benzyl, |
| |
2|halobenzyl, 1-(N-methyl-2-piperidinyl)methyl, |
| |
3|2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, |
| |
4|1-(N-methyl-3-morpholinyl)methyl, (tetrahydropyran-4-yl)methyl, |
| |
5|1-methylazepanyl, phenyl, or halophenyl group, with substitution at |
| |
6|the carbon of the methanone group by an adamantyl, naphthyl, phenyl, |
| |
7|benzyl, quinolinyl, cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, |
| |
8|1-amino-3,3-dimethyl-1-oxobutan-2-yl, |
| |
9|1-methoxy-3-methyl-1-oxobutan-2-yl, |
| |
10|1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether |
| |
11|or not further substituted at the carbazole, adamantyl, naphthyl, |
| |
12|phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any extent. |
| |
13|Carbazole Ketones include, but are not limited to, |
| |
14|naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone (EG-018); |
| |
15| 13. Benzimidazole Ketone: Any compound containing |
| |
16|(benzimidazole-2-yl) methanone structure with or without |
| |
17|substitution at either nitrogen atom of the benzimidazole ring by an |
| |
18|alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, |
| |
19|cycloalkylethyl, benzyl, halobenzyl, |
| |
20|1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, |
| |
21|1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, |
| |
22|(tetrahydropyran-4-yl)methyl, 1-methylazepanyl, phenyl, or |
| |
23|halophenyl group, with substitution at the carbon of the methanone |
| |
24|group by an adamantyl, naphthyl, phenyl, benzyl, quinolinyl, |
| |
Page 54
___________________________________________________________________________
1|cycloalkyl, 1-amino-3-methyl-1-oxobutan-2-yl, |
| |
2|1-amino-3,3-dimethyl-1-oxobutan-2-yl, |
| |
3|1-methoxy-3-methyl-1-oxobutan-2-yl, |
| |
4|1-methoxy-3,3-dimethyl-1-oxobutan-2-yl or pyrrole group, and whether |
| |
5|or not further substituted in the benzimidazole, adamantyl, |
| |
6|naphthyl, phenyl, pyrrole, quinolinyl, or cycloalkyl rings to any |
| |
7|extent. Benzimidazole Ketones include, but are not limited to: |
| |
8| a. |
| |
9| naphthalen-1-yl(1-pentyl-1H-benzo[d]imidazol-2-l)metha |
| |
10| none (JWH-018 benzimidazole analog), or |
| |
11| b. |
| |
12| (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthal |
| |
13| en-1-yl)methanone (FUBIMINA); and |
| |
14| 14. Modified by Replacement: any compound defined in this |
| |
15|subsection that is modified by replacement of a carbon with nitrogen |
| |
16|in the indole, naphthyl, indene, benzimidazole, or carbazole ring. |
| |
17| H. Any prescription drug approved by the federal Food and Drug |
| |
18|Administration under the provisions of Section 505 of the Federal |
| |
19|Food, Drug, and Cosmetic Act, Title 21 of the United States Code, |
| |
20|Section 355, that is designated, rescheduled, or deleted as a |
| |
21|controlled substance under federal law by the United States Drug |
| |
22|Enforcement Administration shall be excluded from Schedule I and |
| |
23|shall be prescribed, distributed, dispensed, or used in accordance |
| |
24|with federal law upon the issuance of a notice, final rule, or |
| |
Page 55
___________________________________________________________________________
1|interim final rule by the United States Drug Enforcement |
| |
2|Administration designating, rescheduling, or deleting as a |
| |
3|controlled substance such a drug product under federal law, unless |
| |
4|and until the State Board of Pharmacy takes action pursuant to |
| |
5|Section 2-201 of this title. If the Board of Pharmacy does not take |
| |
6|action pursuant to Section 2-201 of this title, the drug product |
| |
7|shall be deemed to be designated, rescheduled, or deleted as a |
| |
8|controlled substance in accordance with federal law and in |
| |
9|compliance with the Uniform Controlled Dangerous Substances Act. |
| |
10| SECTION 3. AMENDATORY 63 O.S. 2021, Section 2-208, is |
| |
11|amended to read as follows: |
| |
12| Section 2-208. The controlled substances listed in this section |
| |
13|are included in Schedule III. |
| |
14| A. Unless listed in another schedule, any material, compound, |
| |
15|mixture, or preparation, which contains any quantity of the |
| |
16|following substances or any other substance having a potential for |
| |
17|abuse associated with a stimulant or depressant effect on the |
| |
18|central nervous system: |
| |
19| 1. Any drug product containing gamma-hydroxybutyric acid, |
| |
20|including its salts, isomers, and salts of isomers, for which an |
| |
21|application has been approved under Section 505 of the Federal Food, |
| |
22|Drug, and Cosmetic Act; |
| |
23| 2. Any material, compound, mixture, or preparation which |
| |
24|contains any quantity of the following hormonal substances or |
| |
Page 56
___________________________________________________________________________
1|steroids, including their salts, isomers, esters and salts of |
| |
2|isomers and esters, when the existence of these salts, isomers, |
| |
3|esters, and salts of isomers and esters is possible within the |
| |
4|specific chemical designation: |
| |
5| a. Boldenone, |
| |
6| b. Chlorotestosterone, |
| |
7| c. Clostebol, |
| |
8| d. Dehydrochlormethyltestosterone, |
| |
9| e. Dihydrotestosterone, |
| |
10| f. Drostanolone, |
| |
11| g. Ethylestrenol, |
| |
12| h. Fluoxymesterone, |
| |
13| i. Formebolone, |
| |
14| j. Mesterolone, |
| |
15| k. Methandienone, |
| |
16| l. Methandranone, |
| |
17| m. Methandriol, |
| |
18| n. Methandrostenolone, |
| |
19| o. Methenolone, |
| |
20| p. Methyltestosterone, except as provided in subsection E |
| |
21| of this section, |
| |
22| q. Mibolerone, |
| |
23| r. Nandrolone, |
| |
24| s. Norethandrolone, |
| |
Page 57
___________________________________________________________________________
1| t. Oxandrolone, | | | 2| u. Oxymesterone, | | | 3| v. Oxymetholone, | | | 4| w. Stanolone, | | | 5| x. Stanozolol, | | | 6| y. Testolactone, | | | 7| z. Testosterone, except as provided in subsection E of | | | 8| this section, and | | | 9| aa. Trenbolone; | | | 10| 3. Any substance which contains any quantity of a derivative of | | | 11|barbituric acid, or any salt of a derivative of barbituric acid; | | | 12| 4. Benzephetamine and its salts; | | | 13| 5. Buprenorphine; | | | 14| 6. Butalbital/acetaminophen/caffeine; | | | 15| 7. Chlorhexadol; | | | 16| 8. Chlorphentermine and its salts; | | | 17| 9. Clortermine; | | | 18| 10. Dronabinol; | | | 19| 11. Glutethimide; | | | 20|11.12. Ketamine, its salts, isomers, and salts of isomers; | | | 21|12.13. Lysergic acid; | | | 22|13.14. Lysergic acid amide; | | | 23|14.15. Mazindol; | | | 24|15.16. Methyprylon; | | | Page 58 ___________________________________________________________________________
1|16.17. Phendimetrazine; | | | 2|17.18. Phenylacetone (P2P); | | | 3|18.19. Sulfondiethylmethane; | | | 4|19.20. Sulfonethylmethane; | | | 5|20.21. Sulfonmethane; | | | 6|21.Tetrahydrocannibinols;| | | 7|22. 1-Phenycyclohexylamine; or | | | 8| 23. 1-Piperidinocychexanecarbo nitrile (PCC). | | | 9| Livestock implants as regulated by the Federal Food and Drug | | | 10|Administration shall be exempt. | | | 11| B. Nalorphine. | | | 12| C. Unless listed in another schedule, any material, compound, | | | 13|mixture, or preparation containing limited quantities of any of the | | | 14|following narcotic drugs, or any salts thereof: | | | 15| 1. Not more than one and eight-tenths (1.8) grams of codeine or | | | 16|any of its salts, per one hundred (100) milliliters or not more than | | | 17|ninety (90) milligrams per dosage unit, with an equal or greater | | | 18|quantity of an isoquinoline alkaloid of opium; | | | 19| 2. Not more than one and eight-tenths (1.8) grams of codeine or | | | 20|any of its salts, per one hundred (100) milliliters or not more than | | | 21|ninety (90) milligrams per dosage unit, with one or more active, | | | 22|nonnarcotic ingredients in recognized therapeutic amounts; | | | 23| 3. Not more than one and eight-tenths (1.8) grams of | | | 24|dihydrocodeine or any of its salts, per one hundred (100) | | | Page 59 ___________________________________________________________________________
1|milliliters or not more than ninety (90) milligrams per dosage unit, |
| |
2|with one or more active, nonnarcotic ingredients in recognized |
| |
3|therapeutic amounts; |
| |
4| 4. Not more than three hundred (300) milligrams of |
| |
5|ethylmorphine or any of its salts, per one hundred (100) milliliters |
| |
6|or not more than fifteen (15) milligrams per dosage unit, with one |
| |
7|or more ingredients in recognized therapeutic amounts; |
| |
8| 5. Not more than five hundred (500) milligrams of opium per one |
| |
9|hundred (100) milliliters or per one hundred (100) grams, or not |
| |
10|more than twenty-five (25) milligrams per dosage unit, with one or |
| |
11|more active, nonnarcotic ingredients in recognized therapeutic |
| |
12|amounts; or |
| |
13| 6. Not more than fifty (50) milligrams of morphine or any of |
| |
14|its salts, per one hundred (100) milliliters or per one hundred |
| |
15|(100) grams with one or more active, nonnarcotic ingredients in |
| |
16|recognized therapeutic amounts. |
| |
17| D. The Board of Pharmacy may except by rule any compound, |
| |
18|mixture, or preparation containing any stimulant or depressant |
| |
19|substance listed in subsections A and B of this section from the |
| |
20|application of all or any part of the Uniform Controlled Dangerous |
| |
21|Substances Act if the compound, mixture, or preparation contains one |
| |
22|or more active medicinal ingredients not having a stimulant or |
| |
23|depressant effect on the central nervous system, and if the |
| |
24|admixtures are included therein in combinations, quantity, |
| |
Page 60
___________________________________________________________________________
1|proportion, or concentration that vitiate the potential for abuse of |
| |
2|the substances which have a stimulant or depressant effect on the |
| |
3|central nervous system. |
| |
4| E. The following hormonal substances or steroids are exempt |
| |
5|from classification as Schedule III controlled dangerous substances: |
| |
6| 1. Estratest, containing 1.25 mg esterified estrogens and 2.5 |
| |
7|mg methyltestosterone; |
| |
8| 2. Estratest HS, containing 0.625 mg esterified estrogens and |
| |
9|1.25 mg methyltestosterone; |
| |
10| 3. Premarin with Methyltestosterone, containing 1.25 mg |
| |
11|conjugated estrogens and 10.0 mg methyltestosterone; |
| |
12| 4. Premarin with Methyltestosterone, containing 0.625 mg |
| |
13|conjugated estrogens and 5.0 mg methyltestosterone; |
| |
14| 5. Testosterone Cypionate - Estrodiol Cypionate injection, |
| |
15|containing 50 mg/ml Testosterone Cypionate; and |
| |
16| 6. Testosterone Enanthate - Estradiol Valerate injection, |
| |
17|containing 90 mg/ml Testosterone Enanthate and 4 mg/ml Estradiol |
| |
18|Valerate. |
| |
19| SECTION 4. This act shall become effective November 1, 2026. |
| |
20| Passed the Senate the 25th day of February, 2026. |
| |
21| |
| |
22| |
| Presiding Officer of the Senate |
23| |
| |
24| |
| |
Page 61
___________________________________________________________________________
1| Passed the House of Representatives the ____ day of __________, |
| |
2|2026. |
| |
3| |
| |
4| |
| Presiding Officer of the House |
5| of Representatives |
| |
6| |
| |
7| |
| |
8| |
| |
9| |
| |
10| |
| |
11| |
| |
12| |
| |
13| |
| |
14| |
| |
15| |
| |
16| |
| |
17| |
| |
18| |
| |
19| |
| |
20| |
| |
21| |
| |
22| |
| |
23| |
| |
24| |
| |
Page 62